| lixisenatide vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lixisenatide vs exenatide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | all hypoglycemia | no data | | severe hypoglycemia | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | A CHANGER | no data | | vomiting | no data | | diarrhoea | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lixisenatide vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lixisenatide vs placebo (add on basal insulin) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lixisenatide vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | all hypoglycemia | no data | | severe hypoglycemia | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | A CHANGER | no data | | vomiting | no data | | diarrhoea | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lixisenatide vs placebo (add on MET+/-SU) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lixisenatide vs placebo (add on SU+/-MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lixisenatide vs placebo (add on TZD+/-MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lixisenatide vs sitagliptin (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on MET+SU therapy : 1 trials - GetGoal-M-As
| lixisenatide vs placebo (add on MET+/-SU) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on metformin: 3 trials - EFC10780 - Ratner DRI6012 - GETGOAL-M
| lixisenatide vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | all hypoglycemia | no data | | severe hypoglycemia | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | A CHANGER | no data | | vomiting | no data | | diarrhoea | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lixisenatide vs sitagliptin (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on monotherapy : 4 trials - EFC10780 - Ratner DRI6012 - GETGOAL-M - GETGOAL-L-ASIA
| lixisenatide vs placebo (add on basal insulin) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lixisenatide vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | all hypoglycemia | no data | | severe hypoglycemia | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | A CHANGER | no data | | vomiting | no data | | diarrhoea | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lixisenatide vs sitagliptin (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled with insulin: 3 trials - GetGoal Duo1 - GETGOAL-L - GETGOAL-L-ASIA
| lixisenatide vs placebo (add on basal insulin) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with insufficient glycaemic control with bitherapy: 4 trials - GetGoal-M-As - GetGoal Duo1 - GETGOAL-S - GETGOAL-P
| lixisenatide vs placebo (add on basal insulin) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lixisenatide vs placebo (add on MET+/-SU) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lixisenatide vs placebo (add on SU+/-MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lixisenatide vs placebo (add on TZD+/-MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
